HESTERBIO Q4 FY26 Earnings Call Transcript & Analysis
Net Debt ₹70 cr. Standalone Q4 revenue grew by 22%, with PAT increasing by 174%.
Read full transcript & analysis
Every earnings call for HESTERBIO — management tone, guidance, KPIs and promise tracking, quarter by quarter.
HESTERBIO · 6 transcripts · Healthcare · latest Q4 FY26Hester Bios has 6 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Net Debt ₹70 cr. Standalone Q4 revenue grew by 22%, with PAT increasing by 174%.
Read full transcript & analysisStand-alone Revenue Growth 0.12% (+12% YoY); Stand-alone PAT Growth 1.4% (+140% YoY); 9M Stand-alone Revenue Growth -0.05% (−5% YoY). Stand-alone revenue grew 12% in Q3 FY26, with PAT up 140% YoY.
Read full transcript & analysisStand-alone Q3 Revenue Growth 0.12% (+12% YoY); Stand-alone Q3 PAT Growth 1.4% (+140% YoY); Stand-alone 9M Revenue Growth -0.05% (−5% YoY). Q3 stand-alone revenue grew by 12%.
Read full transcript & analysisStandalone Revenue ₹63 cr (−14% YoY). Consolidated PAT grew over 100% YoY.
Read full transcript & analysisHester Nepal Net Profit ₹1 cr; Hester Africa Net Loss ₹10 cr. Standalone profit grew by 17% for FY25 and 30% in Q4.
Read full transcript & analysisConsolidated profit grew by 85% for 9 months compared to the previous year.
Read full transcript & analysis